Dexrazoxane (Savene) is the standard therapy for anthracycline extravasation Dexrazoxan (Savene) als Standard in der Therapie von Anthrazyklinparavasaten

Mundhenke C (2010)

Publication Type: Journal article

Publication year: 2010

Journal

Chirurgische Praxis Hans Marseille Vertrieb Medizinische Zeitschriften

Book Volume: 72

Pages Range: 447-448

Journal Issue: 3

Abstract

Numerous cytotoxic substances show serious tissue damage when extravasation occurs. Especially anthracyclines can cause severe and progressive tissue damage, which rapidly develops after extravasation. In two prospective clinical trials the topoisomerase Il inhibitor dexrazoxane (Savene) proved to be protective against tissue damage after anthracycline extravasation. Therefore dexrazoxane should be the standard therapy after anthracycline extravasation. Chemotherapy units should have dexrazoxane available for emergency application.

Authors with CRIS profile

Christoph Mundhenke

Involved external institutions

Universitätsklinikum Schleswig-Holstein (UKSH) DE Germany (DE)

How to cite

APA:

Mundhenke, C. (2010). Dexrazoxane (Savene) is the standard therapy for anthracycline extravasation Dexrazoxan (Savene) als Standard in der Therapie von Anthrazyklinparavasaten. Chirurgische Praxis, 72(3), 447-448.

MLA:

Mundhenke, Christoph. "Dexrazoxane (Savene) is the standard therapy for anthracycline extravasation Dexrazoxan (Savene) als Standard in der Therapie von Anthrazyklinparavasaten." Chirurgische Praxis 72.3 (2010): 447-448.

BibTeX: Download